Nov 7 (Reuters) - Regenxbio Inc ::REGENXBIO REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND ANNOUNCES INITIATION OF PHASE I/II CLINICAL TRIAL FOR RGX-121 FOR THE TREATMENT OF MPS II.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.$475 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30.
Full Article
Nov 5 (Reuters) - Abeona Therapeutics Inc ::ABEONA THERAPEUTICS AND REGENXBIO ANNOUNCE WORLDWIDE EXCLUSIVE LICENSES FOR THE TREATMENT OF FOUR RARE LYSOSOMAL STORAGE DISORDERS USING NAV AAV9 VECTOR.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $20 MILLION UPFRONT.ABEONA THERAPEUTICS INC - ABEONA TO PAY REGENXBIO $10 MILLION PAID UPON SIGNING, $10 MILLION BY FIRST ANNIVERSARY OF AGREEMENT.ABEONA THERAPEUTICS INC - ANNUAL PAYMENTS OF $20 MILLION GUARANTEED PAYABLE UPON SECOND ANNIVERSARY OF AGREEMENT.
Full Article
Aug 10 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.70 MILLION COMMON SHARES PRICED AT $65.00PER SHARE.
Full Article
June 11 (Reuters) - Regenxbio Inc ::REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS.REGENXBIO - ACCELERATED LICENSE PAYMENT CONSISTED OF $60 MILLION IN ANNUAL FEES AND A COMMERCIAL MILESTONE FEE OF $40 MILLION.REGENXBIO INC - NOVARTIS NOW HOLDS EXCLUSIVE RIGHTS TO NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO INC - REGENXBIO REMAINS ELIGIBLE TO RECEIVE A POTENTIAL COMMERCIAL MILESTONE FEE.
Full Article
March 6 (Reuters) - Regenxbio Inc ::REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.Q4 REVENUE $2.0 MILLION.QTRLY LOSS PER SHARE $0.51.REITERATES THAT IT EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.
Full Article
Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.
Full Article
Jan 4 (Reuters) - Regenxbio Inc ::REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE.- ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018.- ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018.- ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.
Full Article
Dec 19 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II.REGENXBIO INC - EXPECT TO COMMENCE TRIAL ENROLLMENT IN FIRST HALF OF 2018 FOR RGX-121.
Full Article
Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016.
Full Article
Oct 5 (Reuters) - RTW Investments:RTW Investments reports a 5 percent passive stake in Regenxbio Inc as of October 2, 2017 - SEC filing.
Full Article
Earnings vs. 
Estimates